NextCure Seeks Court Validation of 2025 Reverse Split Amid Merger Uncertainty
NXTC has more than doubled off its 52-week low of $1.55.
Summary
NextCure filed a Section 205 petition to validate its 2025 reverse stock split after discovering the vote may have fallen short of the required supermajority. A court hearing is set for November 6, 2026, and an adverse ruling could jeopardize the pending Avere merger.
Key Events · Legal and Risk Events · NXTC
-
Section 205 Petition Filed
NextCure filed a petition in Delaware Court of Chancery on September 14, 2026 seeking validation of its July 10, 2025 reverse stock split amendment and all shares issued in reliance on it.
-
Vote Fell Short of Supermajority
The 2025 reverse split was approved by 64.76% of outstanding shares (18,166,577 for, 2,028,946 against), below the 66 2/3% supermajority standard that may have been required under the company's charter.
-
Merger at Risk
The company warns that if the Section 205 action is unsuccessful, it could delay or prevent completion of the proposed merger with Avere Therapeutics, which is expected to close in November 2026.
-
Court Hearing Scheduled
The Court of Chancery set a hearing for November 6, 2026 at 3:00 p.m. ET. Stockholders wishing to oppose the petition must file written submissions by October 27, 2026.
Analysis · NXTC · Life Sciences
NextCure has asked the Delaware Court of Chancery to validate its July 2025 reverse stock split after discovering the vote may have fallen short of the supermajority standard required by its charter. The 2025 split was approved by 64.76% of outstanding shares, just below the 66 2/3% threshold that may have applied. If the court declines to validate the split, the company's entire post-split capital structure — including shares issued in subsequent financings and the shares to be issued in the pending Avere Therapeutics merger — could be called into question. The court has set a hearing for November 6, 2026, and the company warns that an adverse ruling could delay or derail the merger, which is critical to its future.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 36.7% of the 976 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.68%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NXTC was trading at $5.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.3M. The 52-week trading range was $1.55 to $15.74. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.